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ABSTRACT 
Objectives: A primary outcome in oncology trials is overall survival (OS). However, to 
estimate OS accurately requires a sufficient number of patients to have died, which may 
take a long time. If an alternative endpoint is sufficiently highly correlated with OS, it 
can be used as a surrogate. Progression-free survival (PFS) is the surrogate most often 
used in oncology, but does not always satisfy the correlation conditions for surrogacy. 
We analyse the methodologies used when extrapolating from PFS to OS. Methods: 
Davis, Tappenden (1) previously reviewed the use of surrogate endpoints in oncology, 
using papers published between 2001 and 2011. We extend this, reviewing papers 
published between 2012 and 2016. We also examine the reporting of statistical methods 
to assess the strength of surrogacy. Results: The findings from 2012 to 2016 do not 
differ substantially from those of 2001 to 2011: the same factors are shown to affect the 
relationship between PFS and OS. The proportion of papers reporting individual patient 
data (IPD), strongly recommended for full assessment of surrogacy, remains low: 33%. 
A wide range of methods has been used to determine the appropriateness of surrogates. 
While usually adhering to reporting standards, the standard of scholarship appears 
sometimes to be questionable and the reporting of results often haphazard. Conclusion: 
Standards of analysis and reporting PFS to OS surrogate studies should be improved by 
increasing the rigour of statistical reporting and by agreeing to a minimum set of 
reporting guidelines. Moreover, the use of IPD to assess surrogacy should increase.  
Keywords: cancer, surrogate endpoints, overall survival (OS), progression-free survival 
(PFS), post-progression survival (PPS) 
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INTRODUCTION 
Outcomes from clinical and other healthcare trials of most interest to patients and health 
systems are usually increases in the length and quality of life as a result of treatment. 
This poses a problem, because to estimate overall survival (OS) sufficiently accurately 
often requires long-term follow-up. Direct extrapolation of OS to encompass those 
patients who had not died by the end of the follow-up period may be carried out. 
Although it is the preferred method of the UK´s National Institute of Health and Care 
Excellence (NICE), its use is not always satisfactory (2,3). An alternative is to use 
progression-free survival (PFS) as a surrogate outcome. Trials with an adequate 
surrogate endpoint can be shorter and involve fewer patients, and can thus help to bring 
a new drug or treatment to the market sooner, or allow products to be brought to 
market where the costs of a trial using OS would not be justified by the expected 
returns. This is beneficial to patients and health systems, and improves returns to 
manufacturers.  
However, these benefits are achieved at the expense of a less accurate measure of final 
outcome than would occur by waiting for data such as OS to become available. Thus 
there is a trade-off between time elapsed from the end of study (excluding follow-up) 
before information becomes available, and the accuracy of the information about the 
benefits of treatment. This paper analyses the methodologies and challenges faced when 
using PFS as a surrogate for OS in oncology. 
METHODS 
Davis, Tappenden (1) conducted a literature review on the use of surrogate endpoints in 
oncology up to the end of 2011. They identified 266 articles, using citation searching to 
identify relevant papers from an initial list of three papers already known to the authors. 
They said a systematic literature review was not feasible, because an exploratory search 
returned a very large number of references (over 3,000), and because any attempt to 
make the search more specific resulted in many relevant papers being excluded. 
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Davis, Tappenden (1) included all reviews that examined a statistical relationship 
between OS and either PFS or time to progression (TTP) and considered any form of 
treatment where curing the disease was not expected. Nineteen key articles concerning 
the relationship between PFS/TTP and OS in advanced/metastatic cancer were included. 
We updated the review conducted by Davis, Tappenden (1) to 2016 using similar search 
methods and selection criteria to preserve as much comparability as possible, and using 
the 19 papers identified by them as our key papers upon which to base our citation 
search. We considered only articles in which PFS was mentioned, and excluded those 
articles that analysed only TTP. Davis, Tappenden (1) did not include radiographic 
progression-free survival (rPFS) studies, and so neither did we.  A previous follow-up of 
Davis, Tappenden (1) was carried out by Ciani, Davis (4). Our analysis differs from that 
of Ciani, Davis (4) as our aim has additionally been to examine the statistical 
methodologies most commonly applied as well as the main challenges faced by authors 
when assessing the validity of PFS as a surrogate.  
In August 2016, we conducted a Google Scholar citation search from January 2012 to 
June 2016, identifying a total of 790 articles which had cited any of the original 19 key 
articles identified by Davis, Tappenden (1). We applied four inclusion criteria: 1) 
mentioned PFS and OS in the title; or 2) mentioned PFS as a surrogate (including 
surrogate + outcome/endpoint/measure); or 3) analysis of possible surrogate measures 
in cancer; or 4) analysed endpoints for cancer. An additional seven articles were 
excluded because they are reviews of previous studies of PFS surrogacy. After applying a 
series of exclusion criteria (Figure 1), 48 articles were included in the analysis.  
The 19 papers reviewed by Davis, Tappenden (1) and the 48 in this paper were mostly 
summaries of many studies. For each study within a paper, there was a single aggregate 
data point pair, the average/median PFS and the average/median OS. This pair of points 
was then used as one observation in an analysis that pooled all such pairs from the 
many studies considered in the paper. The sample size for the estimated correlations or 
regression parameters equals the number of studies considered by the paper. Such data 
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are known as aggregated clinical trial data (ACTD), in which large amounts of data (all 
the data points of individuals within each trial) have been ignored. In both Davis, 
Tappenden (1) and our paper, a minority of analyses used unaggregated source data. 
That is, each patient within the study has a pair of observations which is brought 
together in a sample, the size of which is the number of patients, for estimating 
correlations and regression parameters. Such data are known as individual patient data 
(IPD). Information regarding methodology, data and factors affecting the relationship 
between PFS and OS were extracted. Author affiliation and publication journal were also 
collected by KHV. The quality and accuracy of the extraction was verified by AF. 
RESULTS 
The 2012-2016 results from this review are very similar to those of Davis, Tappenden 
(1). Davis, Tappenden (1) usually found a positive correlation between PFS/TTP and OS 
for individual patients, individual trial arms and the treatment effect between trial arms: 
only 10.5% (2/19) of articles did not support the idea that PFS/TTP could be a useful 
surrogate for OS. However, the size of the correlation and its statistical significance 
varied considerably across studies, particularly between cancer types. The authors 
attributed this variation to the dissimilarities in patient characteristics from study to 
study, such as tumour type, line of therapy, and diversity of treatment methods.  
We classified the results into three groups: 1) papers that explicitly mentioned that PFS 
is a good surrogate for OS, 2) those that indicated that PFS could be a good surrogate 
only under certain conditions, and 3) those that concluded that PFS is not a good 
surrogate for OS. Davis, Tappenden (1) (7/12) and our (17/32) analysis both indicate 
that around 55% of the articles using ACTD from multiple trials support PFS surrogacy. 
Eight of the remaining 15 articles in our study do not support surrogacy, while seven 
articles support PFS surrogacy only under particular conditions (e.g. treatment line). 
The lack of IPD is evident if we consider that around 35% of the articles found both by 
Davis, Tappenden (1) (7/19) and by this review (16/48) include IPD data (Table 1). 
Among the 10 articles that used solely IPD in our review, four supported surrogacy, 5 did 
7 
 
not and one supported surrogacy for treatments that have a major impact on PFS. 
Moreover, six of the ten IPD articles in our review were based on information collected in 
a single Japanese institution, which indicates that the conclusions should be viewed with 
caution (5-10). 
Methodologies and statistical results 
In analysing the relationship between PFS and OS, the most usual preference has been 
IRUWKHXVHRIFRUUHODWLRQVXFKDV6SHDUPDQ3HDUVRQRU.HQGDOO¶VĲ71%-34/48) and 
weighted or unweighted linear regression (73%-35/48) (Table 2), comparable to the 
findings of Davis, Tappenden (1). Moreover, like Davis, Tappenden (1), we found that 
many different variations in methodology have been applied which makes it difficult to 
compare the results of studies (e.g. Aboshi, Kaneko (11) and Bria, Massari (12), Table 
2).    
Additionally, out of the seven articles that used Pearson correlation, six support 
surrogacy and one supports surrogacy only for second- or third-line therapy. However, 
from the 21 articles that used Spearman correlation only seven support surrogacy. This 
suggests an effect of the correlation test selected. Pearson correlations are affected by 
outliers more strongly than Spearman correlations; the use of the Pearson correlation 
without considering outliers could lead to misleading conclusions. 
 
A common practice for testing whether the surrogate is capable of predicting the clinical 
end point is to analyse the relationship between the actual values of the PFS and OS. 
Those articles that include ACTD mostly use median PFS and median OS, but in some 
cases the estimation uses a logarithmic transformation of the variables (27). In the case 
of IPD articles, the relationship between the actual values per patient of PFS and OS is 
used to estimate the predictive capacity of PFS.  
The effect of treatment in changing PFS to predict the effect of treatment in changing OS 
is explored throughout the analysis of ACTD. Here it is common to compare hazard ratios 
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(HRs); however, we also identified articles in which the differences in median PFS and 
OS were examined (13,33,41). 
By comparing the distribution of the observations by Surrogacy (Appropriate surrogate 
(AP); Depends on particular factors (DPF); PFS is not an appropriate surrogate (NoAP)) 
(Table 1) with the distribution of the observations split into two depending on the type of 
data (ACTD, IPD or Both), we observe a significant relationship (Fisher's Exact Test 
0.039; Pearson's Chi-squared 0.043) between Surrogacy and Type of data, which 
suggests that the availability of IPD data affects the final conclusion.  
Surrogate threshold effect (STE)  
STE is defined as the minimum treatment effect on the surrogate necessary to predict a 
non-zero effect on the true endpoint (47). It is normally presented as a Hazard Ratio 
(HR), for instance, a STE equal to 0.8 means that a PFS HR smaller than 0.8 would need 
to be observed to predict a less than 1.0 HR for OS.  This concept has the advantage of 
not being a yes or no answer to the question of surrogacy, but a lower bound for PFS 
that if achieved would indicate that a statistically significant effect of the treatment on 
OS can be predicted. STE has been used relatively more frequently since 2012. In Davis, 
Tappenden (1), STE was reported in only two of 19 papers; we identified 11 of 48 
articles (including five of the six articles that included both IPD and ACTD).  However, it 
LVQRWFOHDUZKHWKHU67(LVDIIHFWLQJDXWKRUV¶ILQDOUHFRPPHQGDWLRQV. For instance, 
Foster, Renfro (49) and Shi, De Gramont (50) supported PFS surrogacy with an STE for 
PFS HR smaller than 0.70 while Ciani, Buyse (41) rejected surrogacy with an STE of 0.80 
(Table 3). 
Weaknesses of the current approaches  
1) Lack of rigour in applying methodology.  
Weighted linear regression, the most frequently-used method of analysis, is based on 
assumptions that are not tested in the majority of articles when analysing surrogacy. In 
only a few such cases was the type of model mentioned (14). Exceptions are Félix, 
Aragão (16) that use the Generalized Method of Moments (GMM) to control for 
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heteroscedasticity; and Johnson, Liauw (35) whose results showed unsatisfactory 
diagnostics with non-normality and heteroscedasticity in the residuals. 
Although linear regression assumptions should be so widely known as to be considered 
irrelevant to report them, their absence leaves many analyses open to the suggestion of 
failure to handle complications, such as the presence of outliers. Clear outliers are shown 
in Yoshino, Imai (9) and Moriwaki, Yamamoto (38). Only 23% (11/48) of studies 
consider or mention outliers. In five of the 11 cases authors test the sensitivity of the 
UHVXOWVE\DSSO\LQJDµOHDYH-one-RXW¶VWUDWHJ\(26,47,49,52). The six remaining articles 
test the sensitivity of the results by excluding those trials that are considered outliers 
(13,16,23,24,32,36). 
Publication bias could also have a significant impact on the results, particularly for ACTD. 
Out of the 31 articles that include systematic literature reviews, 11 mentioned 
publication bias as a possible limitation of the study while an additional six articles 
included a step to overcome the possible bias. Among the six, some articles considered 
both published and unpublished clinical trials (15,30,40); the others analysed the extent 
to which ELDVUHSUHVHQWVDSUREOHPXVLQJ(JJHU¶VUHJUHVVLRQWHVW(13,24,41).  
 2) Apparently inconsistent conclusions 
The German Institute of Quality and Efficiency in Health Care (IQWiG) framework 
FRQVLGHUVµORZFRUUHODWLRQ¶to be present when the upper limit (95% confidence interval) 
of the correlation is under 0.70 (Pearson R2 smaller than 0.49) (53). Two out of the five 
articles concerning colorectal cancer that support surrogacy have correlation values 
lower than 0.70 (19,50). For renal carcinoma, Delea, Khuu (13) and Halabi, Rini (44) 
support PFS as a surrogate despite values of association lower than 0.7 (Table 2).   
Petrelli and Barni (20) stand out because of the lack of consistency between supporting 
PFS surrogacy and having results in which R2 (equal to 0.00) and correlation values 
(treatment effect correlation 0.59 and actual values correlation 0.26) are particularly 
low. They observed a weak correlation between PFS and OS for NSCLC. However, they 
still supported PFS as a surrogate for OS, a decision that appears to be influenced by the 
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slope of the linear regression. The slope suggests that a one-month gain in PFS will be 
OLQNHGWRWKUHHZHHNV¶SURORQJDWLRQLQ26+RZHYHUWKHUHDVRQVIRUFRQFOXding that the 
surrogacy is supported remain unclear.  
Table 2 shows inconsistencies between IPD and aggregate approaches (40,42). Foster, 
Renfro (49), based on ACTD, supported surrogacy, while IPD data from the same trial 
were less conclusive. 
Finally, it is possible that different studies analyse PFS surrogacy for a particular cancer 
type by including a similar list of clinical trials. However, it is not possible to observe 
whether similar lists of clinical trials could result in different conclusions since the 
references of the included trials are not mentioned in some of the papers (14).  
Challenges for analysing PFS as a surrogate of OS 
Based on the variables included as part of sensitivity analyses or that have been included 
in multivariate analyses in the papers included in this review, we identify a group of 
factors that could affect the relationship between PFS and OS and appear in at least five 
studies. 
1) Type of treatment and/or therapy (11-22,26,32,33,35,36,38,40-42,47,49,50) 
The literature suggests that the relationship between PFS and OS can be different within 
the same cancer trial depending on the treatment applied or the therapy selected. 
2) Treatment line (14,21,22,25,26,28,33,34,36,40,41,49,52) 
In some cases the analysis cannot validate the surrogacy for first line therapy, as distinct 
from the second or third line therapy, mainly because post-progression survival obscures 
the results of the first line treatments. Petrelli and Barni (32), who analysed 20 first line 
clinical trials, proposed that the decreases in correlation between PFS HR and OS HR 
observed in recent years is likely to be due to the influence of post-progression 
treatments.   
3) Year of the trial (11,13,15,16,18,19,22,28,31-34,40) 
The importance of the year in which the clinical trial was conducted or published was 
explained by the number of drugs available having increased (11 and because the 
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criteria applied to measure progression have changed (e.g. RECIST published in 2000 
was modified in 2010 to mRECIST (54)). 
4) Sub-group of patients or tumour type (10,11,16,18,21,26,32,34,39,52) 
As in Davis, Tappenden (1), the results from the validation of PFS as a surrogate point 
for OS vary substantially between cancer types. Six out of 16 articles for lung cancer 
conclude that PFS is not an appropriate surrogate for OS, and consistency does not 
improve when we consider the line of therapy and the phase of the clinical trial. This 
might be related to the fact that the criteria for supporting surrogacy differ considerably 
between studies. Additionally, it might not be just the observed relationship that is 
changing between studies. This suggests a need to standardise criteria.  
5) Definition of PFS and other measures  
Disease progression is often defined differently between clinical trials. This heterogeneity 
pertains to the period within which patients are evaluated; time intervals between 
radiological and clinical assessments; and what constitutes patient progression (e.g. 
variation of the size of the tumour, and tumour characteristics). There are many other 
forms of heterogeneity, some of which have been mentioned in sub-sections 1) to 4) 
above. The inclusion of Phase II trials is also likely to increase heterogenity. This occurs 
because at most one arm of a dose-determining trial should be featured in a subsequent 
Phase III trial. Arms in which patients are over-dosed and on average die sooner than 
those in the control group should not feature in Phase III trials. Their inclusion in papers 
that measure the correlation between PFS and OS will reduce the estimated correlation. 
Twenty two articles mentioned the problem of heterogeneity as a limitation, but did not 
adjust the methodology in response to the problem. A further seven studies adjusted the 
methodology (18,23,26,31-33,42), two of which included only clinical trials that have the 
same set of progression criteria (RECIST criteria) (23,42). Three of the seven included 
variables such as presence of measurable lesions and tumour response in sensitivity 
analysis (18,31,33). Finally, two  of the seven studies used established definitions to 
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extract the information collected from the clinical trials, regardless of the terminology 
used by the original authors (26,32). 
Additionally, 19 out of the 32 studies based on trial data combined PFS and TTP into a 
single surrogate measure. In addition to progression, PFS includes death as a result of 
any cause while in the case of TTP the event of interest is only disease progression, 
although some authors consider, as part of TTP, deaths caused by the disease in 
question (e.g. Burzykowski, Buyse (55) identified by Davis, Tappenden (1)). All-cause 
mortality can dilute the association between PFS/TTP and OS. Nine of the 19 articles that 
include PFS and TTP analyse the sensitivity of the results by breaking down the articles 
into those that measure PFS and those that measure TTP (13,15,22,25,31-33,38,42). In 
contrast to what we would expect, Delea, Khuu (13), Petrelli and Barni (32) and Shitara, 
Ikeda (15) found that studies that include PFS have a higher correlation with OS 
compared with studies that include TTP. However, Moriwaki, Yamamoto (38) found a 
slightly lower correlation when TTP trials were excluded. 
6) Geographical context (11,14,15,28,33,40) 
A reason given to explain geographical differences in trial results is the variation in 
comparator (i.e. standard) treatments between Asian and occidental countries. In 
addition, in advanced gastric cancer, Shitara, Ikeda (15) pointed out a number of 
differences in tumour characteristics and practice patterns (e.g. surgery and 
chemotherapy) that have been identified between Asian and occidental countries. 
7) Crossover (13,23,30,33,41) 
Some clinical trials allow crossover to the experimental regimen upon disease 
progression. This hinders the analysis of the treatment effect on OS. Eighteen out of the 
32 articles that use ACTD mentioned crossover while six articles considered it during the 
estimation. For renal cell carcinoma, Delea, Khuu (13) indicate that the link between the 
effect of the treatment on PFS and the effect of the treatment on OS was stronger in 
studies that did not allow crossover. In melanoma, Flaherty, Hennig (23) suggested that 
correlation coefficients for the nine trials without crossover were significant and more 
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than 7 percentage points higher than with crossover. Hotta, Suzuki (30), in studying 
NSCLC, suggest that for clinical trials in which the median proportion of crossover was 
lower than 1%, the association between the HRs of PFS and OS was strong. Kim and 
Prasad (56), identified by Davis, Tappenden (1), evaluated previous publications to 
assess the strength of the surrogate-survival correlation among cancer drugs approved. 
They found no significant differences in survival benefit between clinical trials with or 
without crossover. They suggest that the results are opposed to the commonly-shared 
idea that crossover masks OS benefits, possibly because crossover prevents observation 
of late toxicity. Contrary to other studies, in an analysis of colorectal cancer trials, 
Adunlin, Cyrus (33) found that among crossover trials the strength of the association 
between PFS and OS was higher. 
Characteristics of post-progression survival 
Characteristics of post-progression survival (treatment line 1st/2nd/3rd, year of the clinical 
trial, crossover between control and treatment arms, newly diagnosed vs recurrent, and 
sub-group of patients) and the fact that an important number of articles analysed post-
progression survival (PPS) together with PFS suggest that PPS has a role in the 
discussion of the validation of PFS as a surrogate of OS. Amir, Seruga (29) indicate that 
when PPS is short, the correlation between OS and PFS is higher than when PPS is long. 
For patients with advanced NSCLC, Suzuki, Hirashima (37) identified the optimal point of 
correlation of the HR for PFS and the HR for OS by analysing every 1 month of PPS. They 
found that the correlation between the HR for PFS and for OS increases for a PPS of less 
than 6 months and then decreases (<4 months 0.70; <6 months 0.77; <9 months 
0.46). From the 16 articles that analysed PPS, 13 suggest that the relationship between 
OS and PPS is stronger than between OS and PFS and one of the remaining three 
pointed out a high correlation between PFS and PPS.  
A group of Japanese researchers specialising in a study of factors that affect the 
relationship between PPS and OS (5-10) suggests that the significant factors to explain 
the effect of PPS on OS are: 
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x Number of regimens employed after progression   
x Response to the second or third-line treatment  
x Performance status at progression 
x PFS of first line chemotherapy 
x Tumour stage after initial treatment  
x The presence of distant metastases at recurrence  
 
DISCUSSION 
The percentage of articles that conclude that PFS is an appropriate surrogate for OS 
(52%) is higher than the percentage of those that do not support surrogacy (25%). An 
additional 23% of the samples suggest that surrogacy depends on factors such as the 
length of the PPS and whether the treatment was first or subsequent line. In such a 
complicated area, it is no wonder that simple rules of thumb, to determine whether a 
surrogate endpoint can replace OS, will not work in all situations. Additionally, it seems 
that different investigators use different rules of thumb in the same circumstances. 
The first set of criteria to establish whether a surrogate would be an adequate 
replacement for OS was proposed by Prentice (57). His criteria have been amended and 
elaborated since then. Ciani, Davis (4) summarised three different frameworks that are 
currently applied to validate the strength of the evidence (IQWiG, Biomarker-Surrogacy 
Evaluation Schema, DQG(OVWRQDQG7D\ORU¶VIUDPHZRUNV$OOLQFOXGHthe Prentice (57) 
criteria, but also analyse factors that could influence the strength of the relationship, 
such as the quality of the data and characteristics of the clinical trial.  
Ciani, Buyse (58) highlight three further conditions. First, the strength of the association 
between the surrogate endpoint and the final outcome should be measured through 
approaches such as regression and meta-analysis. Second, it is necessary that the effect 
on the final outcome can be predicted and quantified based on the effect on the 
surrogate. The effect of the treatment on PFS must be large enough to predict an 
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improvement in OS. Third, the level of evidence supporting the relationship between the 
surrogate endpoint and the desired outcome needs to be considered. A strong correlation 
should be observed between the surrogate and the end point based on individual patient 
data as well as between the treatment effect on the surrogate end point and the final 
outcomes across multiple randomised trials. Similarly, Buyse, Molenberghs (59) propose 
that to validate a surrogate endpoint, it is necessary to analyse both individual and trial 
level data. ACTD is important for testing the relationship between the treatment effect 
on PFS and the treatment effect on OS while the IPD allows the analysis of the 
relationship between the actual value of PFS and the actual value of OS. Thus, despite 
the existence of recognised surrogate validation criteria, which have been developed 
over time, no consistent application of these criteria was observed in the studies we 
reviewed ± different authors made different, often arbitrary assessments of surrogate 
adequacy. 
The lack of any substantial proportionate increase in the number of articles including IPD 
data between Davis, Tappenden (1) study and our analysis suggests the rate of progress 
in this field is being hampered by an unwillingness by most pharmaceutical companies to 
provide IPD data to independent and well-qualified researchers for analysis or even to 
report analyses based on IPD when those data have routinely been collected.  
Nevertheless, some progress in the topic has been observed, e.g. firms have joined 
recent initiatives such as clinicalstudydatarequest.com or project data sphere that allows 
researchers to analyse pooled IPD data sets.  
The existence of heterogeneity in the definition of progression among clinical trials and a 
lack of clear information in the clinical trial reports as to how disease progression was 
evaluated (15,17,40) indicate that there is a need to standardise clinical trial protocols to 
provide comparability between trials for the same cancer type. 
Finally, our search process found additional evidence that went beyond the scope of 
Davis, Tappenden (1) analysis. Stevens, Philipson (60) outlined an economic approach 
which bears on both clinical effectiveness and on cost effectiveness, suggesting a 
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framework for factoring the use of surrogates into the decision-making process. Perhaps 
surprisingly, the benefits (or costs) of earlier adoption of a new technology that the use 
of a surrogate endpoint will usually allow are not taken into consideration when 
assessing new treatments. The longer the lag between the results of a trial using a 
surrogate endpoint rather than OS, the greater the additional benefits of using a 
surrogate should be, provided the surrogate is valid and that subsequent treatments do 
not act as confounders. However, as Davis Tappenden (1) explain, even when strong 
consistent evidence supporting a correlation between the treatment effects is available, 
it is unclear how that should be converted into a quantified relationship between PFS and 
OS treatment effects within a cost-effectiveness model.  
CONCLUSION 
The analysis strongly suggests that the use of IPD to assess surrogacy should increase. 
A case could be made for release of all IPD as a condition of publication. As in Davis, 
Tappenden (1), our findings show that the availability of such information has been 
limited, though recent data-sharing initiatives may be changing that. 
There is a high variation in the characteristics of the methodologies and little apparent 
consistency in what should be considered appropriate statistical estimation methodology.  
Thus the need for standardisation that allows for more consistent results. 
Standardization, in the form of adhering to common definitions, statistical techniques 
and a checklist of necessary items in reporting results, would often be virtually costless. 
This could facilitate the use of PFS by policy-makers -- if it were deemed appropriate -- 
based upon standardised validation methodology, and could increase both the speed and 
accuracy of their decision-making.  
Many of the factors that affect the validation of surrogacy are related to the length and 
characteristics of post-progression survival. Procedures for gathering information on 
factors affecting the post-progression management of a disease should be described in 
protocols for following-up clinical trial patients, making it possible to derive stronger 
conclusions from statistical analysis. 
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Some limitations of the study need to be mentioned. First, it is not a full literature 
review. We conducted a citation search based on Davis, Tappenden (1) 19 studies that 
we assume captured all relevant articles. Discussions with experts and comparisons with 
previous systematic reviews suggest that no relevant article has been excluded from the 
analysis. Second, this is also not a systematic literature review of any particular cancer 
type. Therefore, analysing whether PFS should or should not be used in any particular 
case was outside of the scope of this analysis. It is recommended that the factors that 
affect the relationship between PFS and OS by cancer type should be analysed in order 
to understand the particular challenges faced in each case. Third, for pragmatic reasons, 
our exclusion of TTP ignores the possibility that the names of TTP and PFS have in error 
been used interchangeably (61). 
Finally, in addition to using one of the frameworks promoted by Ciani, Davis (4) to 
ensure a higher standard of validation of the strength of evidence, both researchers and 
policy-makers in an area that makes use of surrogate endpoints need to be aware that 
the statistical methodology must be properly understood and documented. The 
importance that validating PFS as a surrogate for OS may have on allowing patients to 
access new health technologies more quickly should not be undermined by a poor 
knowledge of the methodology applied. The results of this study are broadly in line with 
those of Kemp and Prasad (62) who have concluded that the use of surrogate outcomes 
should be limited to situations where a surrogate has demonstrated robust ability to 
predict meaningful benefits, or where cases are dire, rare or with few treatment options.  
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